AYOXXA develops multiplex assay for stratification of sepsis patients using soluble biomarkers
- Sepsis today is the third most common cause of death in Germany, with about 160 deaths per day
- Based on its innovative LUNARISTM protein analysis platform, AYOXXA will develop a multiplex immunoassay for the stratification of sepsis patients using soluble biomarkers for use in academic and preclinical research
- "SepsisData.Net.NRW - Digitized pattern recognition for personalized treatment of sepsis patients" is funded by the European Regional Development Fund (ERDF) www.efre.nrw.de
- The kick off meeting was held on September 11 in Bochum
Cologne 25. September 2017 - AYOXXA Biosystems GmbH, an international biotechnology company, will develop a multiplex assay to support the treatment of sepsis patients as part of the project "SepsisData.Net.NRW - Digitized Pattern Recognition for Personalized Treatment of Sepsis Patients". The development will be based on the Company’s innovative bead-based protein analysis platform LUNARIS™.
As a result of the research project, the multiplex assay will be available as a commercial detection kit. It will be marketed initially for use in academic and preclinical research and, after further validation, for routine use in the clinic in the medium term.
The project is funded by the "European Regional Development Fund" (ERDF) and comprises a consortium of North Rhine-Westphalian companies, university hospitals and universities. Head of the project is Prof. Michael Adamzik from the Ruhr University Bochum and the University Hospital Bochum, Department of Anesthesiology, Intensive Care and Pain Therapy. The duration of the project is set for three years.